GO
Loading...

Merck & Co Inc

More

  • FDA approves 41 novel medicines in 2014 vs 27 in 2013. LONDON, Jan 1- U.S. drug approvals in 2014 hit their highest level in 18 years and recommendations in Europe also came at a rapid rate, driven by expensive new treatments for cancer and rare diseases. The U.S. Food and Drug Administration's Center for Drug Evaluation and Research approved 41 novel medicines in...

  • Stocks extend holiday cheer: S&P, Dow end at records Friday, 26 Dec 2014 | 4:00 PM ET
    A trader works on the floor of the New York Stock Exchange.

    Stocks rose in light volume on Friday, with the Dow and S&P 500 closing at records.

  • Dec 23- The U.S. Department of Health and Human Services awarded contracts worth a total of about $43 million to NewLink Genetics Corp and GlaxoSmithKline Plc for faster development of two Ebola vaccines. Under a $30 million contract, NewLink's unit BioProtection Systems Corp will conduct clinical trials to determine the lowest dose at which its vaccine...

  • LOS ANGELES, Dec 23- Express Scripts, the largest manager of prescription drug plans for U.S. employers, is taking an increasingly aggressive stance in price negotiations with pharmaceutical companies after winning discounts on medications with a strategy introduced last year. On Monday, Express Scripts said it lined up a cheaper price for AbbVie Inc's newly...

  • LOS ANGELES, Dec 23- Express Scripts, the largest manager of prescription drug plans for U.S. employers, is taking an increasingly aggressive stance in price negotiations with pharmaceutical companies after winning discounts on medications with a strategy introduced last year. On Monday, Express Scripts said it lined up a cheaper price for AbbVie Inc's newly...

  • Dec 22- The U.S. Food and Drug Administration approved Bristol-Myers Squibb Co's skin cancer drug, more than three months before the scheduled review date. The drug is the second PD-1 inhibitor to be approved by the FDA, the first being Merck& Co Inc's Keytruda in September. The FDA was scheduled to review the drug on March 30.

  • Dec 19- Cubist Pharmaceutical Inc's drug to treat complicated urinary tract and intra-abdominal infections won U.S. approval on Friday, highlighting the regulator's interest in tackling the growing threat of the so-called superbugs. Zerbaxa is the fourth new antibacterial drug approved by the FDA this year. The agency approved Actavis Plc's Dalvance in...

  • Lawyers cash in on favors from state prosecutors Friday, 19 Dec 2014 | 10:54 AM ET
    Gary King speaks during the Democratic Party for New Mexico 2014 Governor Forum in Albuquerque, N.M., May, 2014.

    The partnership is part of an industry pairing plaintiffs' lawyers with state attorneys general to sue companies. The NYT reports.

  • *Shares in GSK partner Agenus jump 10 percent. LONDON, Dec 18- An experimental shingles vaccine from GlaxoSmithKline has produced impressive results in a late-stage study, giving the group's expanding vaccine unit a potential $1 billion boost. The data suggests the British company's new shot could be a strong competitor for Merck& Co's established vaccine...

  • LONDON, Dec 18- An experimental vaccine against shingles from GlaxoSmithKline met its goal in a late-stage study, in a boost for the company's vaccine unit, which is expanding part of its overall healthcare business. The adjuvant includes a component from U.S. biotech firm Agenus, which is entitled to royalties on any future sales. Merck& Co already sells another...

  • Dec 17- Amgen Inc on Wednesday said its new type of treatment for a deadly form of leukemia would cost about $178,000 when it becomes available on Thursday, which would make it one of the world's most expensive cancer drugs. "We believe the price reflects the significant clinical, economic and humanistic value of the product to patients and the healthcare system,...

  • Dec 12- Cempra Inc has no plans for now to sell itself, its CEO said, brushing off talk that the company is a potential target as big drugmakers set their sights on antibiotic developers. The deal stirred speculation that developers such as Cempra could also be takeover targets. I know a lot of other biotechs are, " Cempra Chief Executive Prabha Fernandes said in an...

  • NEW YORK/ WASHINGTON, Dec 11- U.S. prosecutors, already smarting from a appeals court ruling that weakens their ability to crack down on future insider trading, on Thursday faced widening fallout from the decision as some existing cases threatened to unravel. Lawyers for some defendants hinted they might seek to withdraw guilty pleas, and a Manhattan federal...

  • LONDON, Dec 10- Drugmakers are finally getting more bang for their scientific buck, with the rate of return on pharmaceutical research and development increasing for the first time since 2010.. So far this year the U.S. Food and Drug Administration, which acts as gatekeeper to the world's biggest market, has approved 35 new products, up from 27 in the whole of 2013...

  • Stocks recover most of day's losses by the close Tuesday, 9 Dec 2014 | 4:28 PM ET
    Traders on the floor of the New York Stock Exchange.

    Stocks declined on Tuesday, extending losses into a second session, as oil rebounded from a five-year low.

  • Cramer Remix: 3 stocks with long-term potential Monday, 8 Dec 2014 | 7:01 PM ET
    Jim Cramer on Mad Money.

    Toss 'em in your kids' stocking, or be a Grinch and keep them. "Mad Money" host Jim Cramer says buy 'em either way.

  • Cramer's personal connection to Merck acquisition Monday, 8 Dec 2014 | 6:48 PM ET
    A researcher works in a microbiology laboratory at the Cubist Pharmaceuticals research facility in Lexington, Massachusetts.

    Jim Cramer has a personal connection to why he approves of Merck's acquisition of Cubist. Find out why.

  • Trader on the floor of the New York Stock Exchange.

    Stocks declined Monday as trade numbers from China came in below expectations and oil companies were knocked by the falling price of crude.

  • $9.5 billion blockbuster drug deal  Monday, 8 Dec 2014 | 1:01 PM ET

    Following Merck's acquisition of Cubist, chairman and CEO Kenneth Frazier discusses innovation possibilities the deal presents for public health, with CNBC's Meg Tirrell.

  • Cubist options unusually active before Merck deal Monday, 8 Dec 2014 | 12:50 PM ET

    NEW YORK, Dec 8- Cubist Pharmaceuticals Inc options had one of their most active weeks this year last week ahead of Monday's announcement that Merck& Co will buy Cubist for a hefty premium. Merck said it will pay $102 a share for Cubist, 37 percent above the Lexington, Massachussetts, company's closing share price of $74.36 on Friday. Implied volatility jumped to...